Marys Medicine

Euapm.eu


TEACH Summer School
Cascais, Portugal 3-7 July, 2016 Training and Education for
Advanced Clinicians and HCPs
in Personalised Medicine
TEACH Summer School
Cascais, Portugal 3-7 July, 2016 This means that all HCPs in close contact with patients or their patients' families need to be up-to-date with the There are many ways to refer to the core topic of EAPM's current aspects of personalised medicine and its latest education Summer School, such as personalised medicine, breakthroughs in order to better understand their patients' precision medicine, individualised medicine or, if you prefer, stratified medicine.  This inaugural summer school aims to support the For the benefit of commonality, the ground-breaking endeavours of EAPM to set up a Continuous Educational summer school will be centered around the concept of Programme on personalised medicine.
personalised medicine and, for its purposes, this refers to innovative medical interventions tailored to the specific Recognising that the patient is at the centre of his or her needs of individual patients, thus providing better treatment own treatment and health-related decisions, the summer and preventing undesirable adverse reactions while fostering school will focus heavily on training in "how to communicate a more efficient and cost-effective healthcare system.
with patients" in several key areas.
Personalised medicine starts with the patient. It hold huge EAPM and the faculty at this first summer school are potential for improving the health of many patients and convinced that and improvement in such skills among HCPs ensuring better outcomes of health systems' efficiency and is vital to giving the right treatment to the right patient at the Yet, its integration into clinical practice and daily care is proving difficult given the many barriers and challenges to timely access to targeted healthcare that still exist as of today.
If personalised medicine is to be in line with the EU and Member State principle of universal and equal access to high quality healthcare, then clearly it must be made available to many more citizens than it is now. Christine Chomienne, Past President, EHA
Part of what is required is a long-term approach to Louis Denis, Past President, Europa Uomo
education to ensure the translation of new therapies from laboratories to patients.
Summer School Co-Chairs  TEACH Summer School
Cascais, Portugal 3-7 July, 2016 Day One - Sunday 3 July
17:00 - 19:00 Arrival and registration
19:30 - 22:30 Welcome dinner
Day Two - Monday 4 July

Monoclonal antibodies and personalised medicine

Questions addressed by the faculty:
How to target cell surface proteins with a monoclonal antibody? How to kill a cell with a monoclonal antibody? How to enhance or restore a patient's immune system with monoclonal antibodies?  How does one identify a future targetable protein? 08:30 - 09:15 Welcome addresses from the co-chairs of the EAPM Education Summer School
Personalised Medicine: The importance of communicating to patients
Christine Chomienne, Past President, European Hematology Association
Louis Denis, Director Wij Ook/US TOO Belgium
09:15 - 09:30 Patient Literacy and HCP Dialogue
Denis Horgan, EAPM Executive Director
09.30 - 11:00 Plenary Session 1: Monoclonal Antibodies and Targeted Therapies
Session Chair: Peter Riegman, Head of the Erasmus MC Tissue Bank, The Netherlands
09:30 - 10:15 Precision medicine in prevention and early diagnosis of cancer
Angelo Paradiso, IRCCS Foundation - Istituto Tumori Bari

Followed by Q&A
10:15 - 11:00 Monoclonal Antibodies and Solid Tumors
Dr James Spicer, Reader in Experimental Oncology, King's College London, United Kingdom
11:00 - 11.30 Coffee Break
Day Two -Monday 4 July (continued)
11.30 - 13:00 Plenary Session 2: Communication skills
Session Chair: Steve Johnson, Taunton UK
13:00 - 14:00 Lunch

14:00 - 15:30 Plenary Session 3: Monoclonal antibodies


Session chair: Christine Chomienne
, Past President, European Hematology Association
14:00 - 14:45 Monoclonal Antibodies to identify/trigger cell surface targets
Prof. Holger Moch, University Hospital Zurich, Department of Pathology, Switzerland; European Society
of Pathology
14:45 - 15:30 Monoclonal Antibodies - setting the scene at the Political Level

Ricardo Bapista, MP, Portuguese Parliament
15:30 - 16:00 Coffee break
16:00 - 18:00 What is the right treatment for me?
Role Play

Facilitator: Steve Johnson, Taunton UK
19:30 - 22:30 Dinner and speech (Patient-Doctor communication)
Angelo Paradiso, IRCCS Foundation - Istituto Tumori Bari
Day Three - Tuesday 5 July
Inhibitory drugs and personalised medicine
Questions addressed by the faculty:
What are protein kinases? Why are they such important to target?  How does one identify drug that inhibit protein kinases? 09:00 - 10:30 Plenary Session 4: Inhibitors Part I
Session Chair: Christine Chomienne, Past President, European Hematology Association
Day Three - Tuesday 5 July (continued)
09:00 - 09:45 Systems medicine to individualise treatment for asthma
Ian Adcock, Imperial College London, ERS Assembly Head for Airway Diseases
09:45 - 10:30 Inhibitors in Oncology
Paolo G. Casali, ESMO Public Policy Committee Chair
10:30 - 11:00 Coffee Break
11:00 - 13:00 Plenary Session 5: Communication skills

Session Chair: Steve Johnson, Taunton UK
13:00 - 14:00 Lunch
14:00 - 15.30 Plenary Session 6: Inhibitors Part II
Session Chair: Louis Denis, Director Wij Ook/US TOO Belgium
14:15 – 14:45 A clinical trial with inhibitors
Professor Philippe Rousselot, Service d'hématologie et oncologie, CH de Versailles,
Hôpital André Mignot
14:45 – 15:30 Abnormal Tyrosine Kinase inhibitors monitoring

Torsten Haferlach, MLL Leukaemia Labor GmH Munchen
15:30 – 16:00 Coffee break
16:00 - 18:00 - Communication with the patient
Facilitator: Steve Johnson, Taunton UK
19:30 - 22:30 Dinner and speech ('Patient stories')
Luis Mendao, Chair of the Board of GAT - Treatment Activist Group
Day Four - Wednesday 6 July
Patient at the centre of personalised medicine
Questions addressed by the faculty:
Topics on patient information and consent, data sharing and protection 09:00 - 10:30 Plenary Session 7: Adapt treatment to patient
Session Chair: Christine Chomienne, Past President, European Hematology Association
09:00 - 09:45 Biobanking, patient consent and data ownership
Peter Riegman, Head of the Erasmus MC Tissue Bank, Netherlands
09:45 - 10:30 Health literacy and patient information
Denis Horgan, Executive Director, EAPM
Natacha Bolanos, Spanish Group for Cancer Patients, GEPAC
Silvia Riva, University of Milan, Faculty of Oncology and Hemato-oncology
10:30 - 11:00 Coffee break 
11:00 - 13:15 Plenary Session 8: Pharmacogenomics and personalised medicine
Session Chair: Giovanni Codacci Pisanelli, Assistant Professor of Medical Oncology, Rome University

11:00 – 11:45 Clinical utility of genotype-guided Warfarin therapy

Rob Hastings, Senior Manager, Market Development, Illumina

11:45 - 12:30 Personalised medicine and pharmacogenomics

Ron Schaik, Full Professor of Pharmacogenomics and President of ESPT
12:30 - 13:15 Genomics as a tool for precision therapeutics in epilepsy
Gianpiero Cavalleri, RCSI Molecular & Cellular Therapeutics (MCT) Royal College of Surgeons
in Ireland
13:15 - 14:00 Lunch

14:00 - 15:30 Free afternoon (optional visit to Cascais)
Day Four - Wednesday 6 July (continued)
17:00 - 18:30 Programme evaluation, identifying gaps and preparation of
future training programmes
19:30 - 22:30 Dinner and speech (Patient stories)
Peter Kapitein, Inspire2Live

Day Five - Thursday 7 July
09:00 - 10:30 Plenary Session 9: 'Report from the groups'
Session Chairs: Christine Chomienne, Past President, European Hematology Association
Louis Denis, Director Wij Ook/US TOO Belgium
10:30 - 11:00 Coffee Break and group photographs
11:00 - 12:00 Keynote Speech:
Ken Mastris, President, Europa Uomo
12:00 - 13:00 Lunch


About EAPM
The European Alliance for Personalised Medicine (EAPM) , launched in March 2012, brings together European healthcare experts and
patient advocates involved with major chronic diseases.

The aim is to improve patient care by accelerating the development, delivery and uptake of personalised medicine and diagnostics,

As the European discussion on personalised medicine gathers pace. EAPM is a response to the need for wider understanding of
priorities and a more integrated approach among distinct lay and professional stakeholders.
The mix of EAPM members provides extensive scientific, clinical, caring and training expertise in personalised medicine and
diagnostics, across patient groups, academia, health professionals and industry. Relevant departments of the European Commission
have observer status, as does the EMA.
EAPM is funded by its members.
Contact: Denis Horgan
EAPM Executive Director
Avenue de l'Armee/Legerlaan 10, 1040 Brussels
Tel: + 32 4725 35 104

Source: http://euapm.eu/pdf/EAPM_summer_school_agenda.pdf

rahe.in

Ratiram Academy of Higher Education (RAHE) GPAT 2012 ANSWER Q.1. Which of the following respective Phase I and Phase II reactions are the most common drug biotransformation reactions?(A) Oxidation and Glucuronidation(B) Reduction and Acetylation(C) Hydrolysis and Glucuronidation(D) Oxidation and Glutathion conjugationAnswer‐ A

njmr.in

NATIONAL JOURNAL OF MEDICAL RESEARCH print ISSN: 2249 4995│eISSN: 2277 8810 ORIGINAL RESEARCH GONORRHOEA IN MEN: DIAGNOSTIC ASPECTS AND CHANGING ANTIBIOTIC SUSCEPTIBILITY PATTERN Sandeep Nanda1, Sonia Barve1, Chandralekha Bhanujan2, Sachin P Lohra2, Rupal Patel3, Govind L Ninama4, Kalpesh Mistry4 Author's Affiliation: 1Medical college, Baroda; 2BJ Medical College, Ahmedabad; 3PS Medical College, Karamsad; 4GMERS, Gotri, Baroda Correspondence: Dr. Sandeepkumar Nanda, Email: sandeepnanda@rediffmail.com